Clonal hematopoiesis (CH) and trained immunity are emerging immunological processes implicated in the pathophysiology of atherosclerotic cardiovascular disease. The authors note shared molecular features between these phenomena, including a central regulatory role for IL-1β and involvement of epigenetic enzymes. Based on these overlaps, the investigators hypothesized that presence of clonal hematopoiesis driver mutations (CHDMs) could predispose individuals to an increased capacity to develop trained immunity.
This analysis used a previously characterized cohort of older individuals with overweight and obesity. From that cohort the study selected two groups: 17 individuals with clonal hematopoiesis attributed to DNMT3A mutations and 15 individuals without any known CHDMs. The source does not provide additional demographic or comorbidity breakdowns beyond the description of the parent cohort as older adults with overweight and obesity.
Researchers performed in-depth immune characterization using flow cytometry and functional assays focused on monocytes and neutrophils. Peripheral blood mononuclear cells (PBMCs) were assessed ex vivo for cytokine production capacity. Neutrophil phenotype was evaluated, including measurement of CD10 expression as a marker of maturation, and functional responses such as myeloperoxidase (MPO) release following stimulation through pattern-recognition receptors.
To measure capacity for trained immunity, the investigators used established in vitro stimuli: β-glucan and oxidized LDL (oxLDL). These agents were applied in functional assays designed to assess the propensity of monocytes/PBMCs to develop a hyperresponsive, trained phenotype upon secondary stimulation.
The study corroborated earlier observations from the cohort that PBMCs from individuals carrying DNMT3A mutations exhibited lower ex vivo cytokine production capacity. Despite this baseline reduction, the presence of DNMT3A CHDMs was associated with a higher trained immunity response when assessed with β-glucan and oxLDL training protocols. In other words, individuals with DNMT3A-driven CH showed increased susceptibility to develop a hyperresponsive trained monocyte phenotype in the in vitro assays employed by the investigators.
Participants with DNMT3A mutations were characterized by a higher frequency of CD10+ mature neutrophils. Functionally, these participants displayed a lower neutrophil MPO release upon TLR2 stimulation compared with individuals without known CHDMs. These findings indicate that DNMT3A CHDMs are associated with altered innate immune cell composition and function beyond monocyte training capacity.
The authors emphasize convergent mechanisms between clonal hematopoiesis and trained immunity, noting roles for IL-1β and epigenetic regulation. They propose that CHDMs in DNMT3A may predispose to enhanced trained immunity responses, which could be relevant for vasculometabolic complications in people with obesity. However, the source clearly states that the exact molecular mechanisms underlying the association between DNMT3A CHDMs and increased trained immunity remain to be defined and require further investigation.
The research protocol was approved by the Radboud University Ethical Committee (NL72552.091.20; 2020-6135), and all subjects provided written informed consent. The authors state that all relevant ethical guidelines were followed. Data produced in the study are available upon reasonable request to the authors. Competing interest statements reported that most authors have no disclosures; one author declared a scientific founder role in named companies. Funding sources listed in the source include Hartstichting and IN CONTROL II; CVON2018-27.
The source does not provide detailed numerical breakdowns beyond the group sizes (17 with DNMT3A CH and 15 without CHDMs) nor detailed demographic or clinical covariate adjustments. The authors explicitly note that the precise molecular mechanisms behind the observed associations were not determined in this report and require additional study.
In this cohort of older adults with overweight and obesity, presence of DNMT3A clonal hematopoiesis driver mutations was associated with lower baseline PBMC cytokine production but an increased capacity to develop trained immunity in vitro and with altered neutrophil phenotype and function. The findings support an association between DNMT3A-driven CH and enhanced trained monocyte responsiveness, while underscoring that mechanistic explanations remain to be established.